News by topic

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Long-acting HIV treatment news

Show

From To
New and experimental HIV treatments
ViiV Healthcare launches phase III programme to evaluate a long-acting, injectable HIV treatment regimen

Studies will investigate monthly dosing with injectable cabotegravir and rilpivirine

Published
21 November 2016
From
ViiV press release
PrEP
The ‘long tail’ problem: injected-PrEP trial will be extended due to persistence of drug in companion study

A study presented at last month’s HIV Research for Prevention (HIVR4P) conference in Chicago shows that in a minority of subjects who were given an experimental

Published
11 November 2016
By
Gus Cairns
New and experimental HIV treatments
New long-acting fusion inhibitor albuvirtide plus boosted protease inibitor matches standard triple-drug therapy

A new fusion inhibitor, albuvirtide, under development in China, combined with a boosted protease inhibitor, proved just as effective as a triple regimen of lopinavir/ritonavir plus two

Published
28 October 2016
By
Keith Alcorn
PrEP
More Surprises From ÉCLAIR: Cabotegravir's 'Long Tail'

The long-acting injectable cabotegravir (ViiV Healthcare), a novel HIV prevention therapy, can persist in the body for more than a year in some people, surprising new data from the phase 2a ÉCLAIR study show. "It's an important finding because you need to give patients some sense of when that protection ends," said Jeanne Marrazzo, MD, from the University of Alabama at Birmingham.

Published
26 October 2016
From
Medscape (requires free registration)
New and experimental HIV treatments
Long-acting injectable drugs work well for HIV maintenance therapy

Two long-acting injectable antiretrovirals – cabotegravir and rilpivirine – administered once every 4 or 8 weeks maintained viral suppression in people who switched regimens with undetectable viral load,

Published
22 July 2016
By
Liz Highleyman
New and experimental HIV treatments
The HIV Treatment Pipeline

“Depending on when you test positive for HIV, you could be looking at up to eight decades of treatment,” says Tim Horn of Treatment Action Group. “We need drugs that are gentler, kinder, better and cheaper.”

Published
28 June 2016
From
Poz
New and experimental HIV treatments
Frontier Biotech's Long-acting HIV-1 Fusion Inhibitor Albuvirtide Meets 48-Week Primary Objective: Interim Results of a Phase 3 Trial

Frontier Biotechnologies Inc. today reported that a phase 3 clinical trial (TALENT Study) of its lead product albuvirtide meets primary objective based on an interim analysis. The results demonstrated that once-weekly given albuvirtide plus ritonavir-boosted lopinavir was non-inferior to WHO-recommended second-line three-drug regimen (control) at 48-week in treatment experienced HIV-1 infected adults. In addition, patients administered with albuvirtide showed statistically better renal safety than those taking the control regimen containing tenofovir disoproxil fumarate.

Published
07 June 2016
From
Frontier Biotech press release
New and experimental HIV treatments
Long-acting oral antiretroviral MK-8591 could represent 'paradigm shift' in HIV treatment and prophylaxis

An investigational antiretroviral agent that maintains drug levels that are able to inhibit HIV up to six months after dosing could represent a “paradigm shift” in HIV

Published
01 April 2016
By
Michael Carter
PrEP
What is a drug “tail,” and what does it have to do with long-acting PrEP?

Drug “tails” are a hot topic at CROI 2016 as attendees wait to hear results from a long-acting cabotegravir PrEP injection study with HIV-negative men. A few prominent researchers have already incorporated the issue of drug “tails” into their discussions of one potential downside to having a PrEP drug that stays in a person’s system for an extended length of time.

Published
25 February 2016
From
BETA blog
New and experimental HIV treatments
Long-acting injectable cabotegravir + rilpivirine works well as HIV maintenance therapy

A combination of two long-acting injectable antiretrovirals, cabotegravir and rilpivirine, given once every 4 or 8 weeks, maintained viral suppression as well as a standard oral antiretroviral therapy

Published
23 February 2016
By
Liz Highleyman
← Prev1...34567Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.